BERKELEY HEIGHTS, N.J., May 14, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (“Cyclacel” or the “Company”) announced today completion of enrollment of the Phase 2 portion of the investigator-initiated, Phase 2/3 multicenter, randomized trial comparing sapacitabine to low dose cytarabine (the “Pick a Winner Programme / LI-1 Trial”) in patients aged 60 years or older with previously untreated acute myeloid leukemia (AML) or high risk myelodysplastic syndromes (MDS) who are unfit for intensive chemotherapy. The study is being conducted by the U.K.'s Leukaemia Lymphoma Research and U.K. National Cancer Research Institute (NCRI) Working Group.1 The study has reached the accrual goal of approximately 100 patients. More than 40% of patients are still alive and longer follow-up is needed to assess overall survival.
